EFFECT OF INTERFERON ON CELLS PERSISTENTLY INFECTED WITH HUMAN T CELL LEUKEMIA VIRUS (HTLV-I) NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


EFFECT OF INTERFERON ON CELLS PERSISTENTLY INFECTED WITH HUMAN T CELL LEUKEMIA VIRUS (HTLV-I)

Tumor Res; 25:1-6 1990. Unique Identifier : AIDSLINE ICDB/92678241
Fujii N; Kwon KW; Isogai E; Isogai H; Indoh T; Murakami T; Kimura K; Sekiguchi S; Oguma K; Dept. of Microbiology, Sapporo Medical Coll., S1, W17, Sapporo; 060, Japan

Abstract: Spontaneous production of interferon-gamma (IFN-gamma) was shown in 4 (MT-1, MT-2, SMT-1 and HUT 102) of 5 human T-lymphoblastoid cell lines persistently infected with HTLV-I (MT-1, MT-2, SMT-1, HUT 102 and OKM-2). The 4 cell lines were not susceptible to the antivirus effect of IFN. In contrast, the multiplication of vesicular stomatitis virus (VSV) was restricted in the nonproducer cell line of IFN, OKM-2 cells, by treatment with IFN-alpha or IFN-gamma. The antiproliferation effect of IFN was investigated in producer cell lines (MT-2 and SMT-1) and nonproducer cell line (OKM-2) of IFN. The growth of MT-2 cells was not affected by IFN-alpha or by IFN-gamma. However, SMT-1 and OKM-2 cells were affected by treatment with externally added IFN-alpha. (13 Refs)
Keywords: Animal Cell Division/*DRUG EFFECTS Cell Line Human HTLV-I/*DRUG EFFECTS/IMMUNOLOGY Interferon Type II/BIOSYNTHESIS/*PHARMACOLOGY Interferon-alpha/BIOSYNTHESIS/*PHARMACOLOGY Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated/IMMUNOLOGY/ *PATHOLOGY Tumor Cells, Cultured/*DRUG EFFECTS/IMMUNOLOGY Virus Replication/DRUG EFFECTS/IMMUNOLOGY JOURNAL ARTICLEKWDanimalcelldivision/KWDdrugeffectscelllinehumanhtlv-i/KWDdrugeffects/immunologyinterferontypeii/biosynthesis/KWDpharmacologyinterferon-alpha/biosynthesis/KWDpharmacologyleukemia-lymphoma,t-cell,acute,htlv-i-associated/immunology/KWDpathologytumorcells,cultured/KWDdrugeffects/immunologyvirusreplication/drugeffects/immunologyjournalarticle
920228
M9220889

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .